For decades, a serious diagnosis came with an unspoken directive: look beyond Nigeria’s borders for solutions. That reflex, however, is beginning to fade.
In Lagos, a new standard in prostate cancer care is taking shape, driven by advanced robotics, grounded in local expertise, and backed by a growing confidence that world-class treatment can be delivered within Nigeria.
This shift is not rhetorical but measurable. At The Prostate Clinic (TPC) in Lagos, more than 100 robotic-assisted prostate cancer surgeries have been performed within a single year, an outcome that signals both technical capability and institutional intent. It places Nigeria within a global conversation it has too often been excluded from, not by potential, but by infrastructure.
The significance becomes clearer when set against a familiar pattern. For years, patients with complex conditions have looked outward, often at great cost. The African Export-Import Bank estimates that Nigeria loses about $1.1 billion annually to medical tourism. That figure is not just economic leakage; it reflects a system that has struggled to retain both trust and capacity.
Yet here, there is evidence of recalibration.
Patients are no longer only leaving, they are arriving. Beyond Nigerians, individuals from Canada, the United Kingdom, the United States, Brazil, Ghana, Togo, and other African countries have sought treatment at the Lagos-based facility. This is not a symbolic reversal; it is a practical one, grounded in outcomes.
Still, the broader reality remains urgent. Prostate cancer continues to rise in Nigeria, with mortality rates heavily shaped by late presentation. Among men of Black heritage, particularly those aged 40 and above, the risk is significantly higher, with studies indicating that one in four will develop the disease in their lifetime.
The contrast with more developed health systems is stark. In London, about 12.5 per cent of prostate cancer cases are diagnosed at an incurable stage. In Nigeria, that figure exceeds 80 per cent. By then, treatment options narrow sharply, and survival prospects diminish.
For Prof. Kingsley Ekwueme, a UK-trained consultant urologist and robotic surgeon, these are not abstract comparisons. They are the basis of a deliberate return.
“I have been planning to return to my country for over 10 years to do what I do in the UK,” he said. “Only a few can afford to travel for treatment, and that gap needed to be closed.”
His response was to build. Establishing TPC meant replicating a level of care he had long delivered abroad, this time within Nigeria, and accessible to a broader population.
At the centre of that effort is the Da Vinci robotic system, widely regarded as the gold standard in robotic surgery and currently available only at TPC within the country. But technology alone does not shift outcomes as the deeper challenge lies in awareness and timing.
Prostate cancer often advances silently. Early stages present no clear symptoms, which is why many cases are detected late. When symptoms do appear, frequent nighttime urination, weak urine flow, urgency, or erectile dysfunction, the disease may already be advanced.
The implication is straightforward: early detection determines survival.
Routine screening, particularly through Prostate-Specific Antigen (PSA) testing, remains critical, especially for men over 45 or those with a family history. When identified early, prostate cancer is not only treatable but curable.
“At that stage, it can be cured,” Ekwueme said, pointing to patients who have undergone successful procedures and are expected to live full life spans. Over the past year alone, the clinic has treated patients from Nigeria, Ghana, Cameroon, Côte d’Ivoire, Brazil, the United States, the UK, and Canada.
Expansion is already part of the equation. Plans are in place to establish a robotic oncology centre in Imo State, in partnership with the state government, extending access beyond Lagos.
For TPC’s Chairman, Francis Ogboro, the clinic’s trajectory reflects deliberate standards rather than isolated success. Delivering care at a global level, he noted, is not aspirational, it is expected. Increasingly, patient outcomes are validating that position.
Among those outcomes is the experience of Major General John Enenche (retd.), former Director of Media Operations at the Defence Headquarters, who reported a full recovery following treatment. After assessing the clinic’s approach and engaging directly with its leadership, he proceeded with confidence and regained his health.
Veteran journalist Ben Alozie offers further evidence. After undergoing surgery in 2022, a PET scan in 2024 showed no residual cancer cells. His conclusion is clear and grounded in experience: prostate cancer is not a death sentence.
Taken together, these developments point to something more than progress within a single facility but suggest a shift in trajectory, one where Nigeria is not defined solely by its healthcare gaps, but increasingly by its capacity to close them.
The work is not complete. Late diagnosis remains a national challenge, and access must continue to expand but the direction is becoming harder to ignore.
In this moment, Lagos is doing more than treating patients. It is reshaping expectations of what is possible, and where it can happen.
No comments:
Post a Comment